FBRX Forte Biosciences, Inc.

CIK 0001419041 48 ready 8-Ks latest August 27, 2026, 4:15 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 48

Latest filing August 27, 2026, 4:15 PM ET

Top materiality 1.00

Event mix other_material ×23 · earnings ×13 · other ×5

Sentiment 7 pos · 3 neg · 38 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for FBRX

Highest-materiality recent filing

Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned

August 27, 2026, 4:15 PM ET M&A materiality 1.00 neutral item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.
Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.

Read filing →

August 27, 2026, 4:15 PM ET M&A materiality 1.00 neutral item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned

Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.
July 27, 2026, 6:06 AM ET M&A materiality 0.90 positive item 1.01 item 7.01 item 9.01

argenx to acquire Forte Biosciences for $77/share (~$2.2B); adds anti-CD122 antibody FB102

argenx to acquire Forte Biosciences for $77/share in cash, total equity value ~$2.2B.
July 9, 2026, 8:05 AM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement

FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.
June 2, 2026, 4:01 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares

Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.
May 14, 2026, 4:42 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01 ◈ Earnings Releases

Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April

Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.
April 9, 2026, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share

Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.
April 1, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026

Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.
November 14, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026

Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.
August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 8.01 item 9.01

Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data

Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.
June 25, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Forte Biosciences prices $75M public offering of stock and warrants

Priced 5,630,450 shares at $12.00/share and 619,606 pre-funded warrants at $11.999/warrant.
June 23, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating

Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).
May 30, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

Forte Biosciences annual meeting elects directors; auditor ratification approved

Elected Richard Vincent, Shiv Kapoor, and David Gryska as Class II directors until 2028.
May 15, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed

Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.
April 18, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01

Forte Biosciences sets annual meeting for May 29, 2025; proposals due April 28

Annual meeting scheduled for May 29, 2025, more than 30 days before the 2024 anniversary.
April 4, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025

FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.
January 24, 2025, 6:59 PM ET other material materiality 0.50 neutral item 5.02 item 5.07 item 9.01

Forte Biosciences stockholders approve amended equity plan adding 3.34M shares

Stockholders approved A&R 2021 Equity Incentive Plan on Jan 24, 2025; 2.19M for, 0.47M against, 1.38M abstain.
December 3, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

Forte Biosciences hosts R&D Day focusing on FB102 autoimmune updates

R&D Day held December 3, 2024 highlighting FB102 development in autoimmune indications.
November 20, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development

Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.
November 14, 2024, 6:59 PM ET other material materiality 0.60 neutral item 2.02 item 9.01

Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M

Dosing begun in celiac disease trial; topline data expected Q2 2025.
September 20, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 ◈ executive_change ×4

Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M

Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.
August 30, 2024, 7:59 PM ET other material materiality 0.70 neutral item 3.03 item 5.03 item 8.01 item 9.01

Forte Biosciences implements 1-for-25 reverse stock split effective August 28, 2024

Reverse stock split at 1-for-25 ratio effective 8:00 a.m. ET on August 28, 2024.
August 22, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 7.01 item 9.01

Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28

Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.
August 14, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 8.01 item 9.01

Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts

Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).
June 14, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024

Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.
May 13, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing

Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).
March 18, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort

Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.
February 16, 2024, 6:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes

Forte Biosciences board sets advisory vote on executive pay every three years

Stockholders at Sept. 19, 2023 annual meeting cast highest votes for annual say-on-pay, second highest for triennial.
December 8, 2023, 6:59 PM ET other material materiality 0.40 neutral item 4.01 ◈ Auditor Changes

Forte Biosciences appoints KPMG as new independent auditor for FY2023

Audit Committee approved KPMG LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2023.
September 26, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01 ◈ Shareholder Votes ×6

Forte Biosciences reports final 2023 annual meeting results; say-on-pay fails

Two Class III directors elected: Eichenfield (16.4M for) and Wagner (16.8M for); McIntyre and Hacke not elected.
September 20, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Forte Biosciences receives Nasdaq bid price deficiency notice; 180 days to comply

Received Nasdaq notice on Sept 14, 2023 for bid price below $1.00 for 30 consecutive business days.
September 20, 2023, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×7

Forte Biosciences annual meeting: two directors elected, say-on-pay fails, equity plan approved

Preliminary vote shows Eichenfield (16.4M for) and Wagner (16.8M for) elected; McIntyre and Hacke not elected.
August 4, 2023, 7:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01

Auditor Mayer Hoffman McCann declines reappointment; FY2022 tax-provision controls deemed ineffective

MHM will not stand for re-appointment for FY2024; will cease by new auditor appointment, filing of 2023 10-K, or April 1, 2024.
August 1, 2023, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 3.03 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Forte Biosciences raises $25M in private placement; announces promising FB-102 data in GvHD

Raised ~$25M gross from private placement with top-tier institutional investors; execs and board purchased $1.16M.
June 26, 2023, 7:59 PM ET other materiality 0.15 neutral item 1.01 item 3.03 item 5.08 item 8.01 item 9.01 ◈ Material Agreements

Forte Biosciences extends rights agreement expiration to July 2024; sets 2023 annual meeting for September 19

Amendment No. 1 extends Rights Agreement expiration to 5:00 p.m. ET on July 12, 2024, unless earlier redeemed or exchanged.
March 31, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024

Net loss of $13.9M ($0.80/sh) vs $21.7M ($1.55/sh) in FY 2021; cash and equivalents $41.1M at year-end.
February 9, 2023, 6:59 PM ET other materiality 0.25 neutral item 5.03 item 9.01 ◈ Governance Changes

Forte Biosciences amends bylaws to update stockholder meeting procedures

Bylaws revised to require stockholder nominating directors to deliver evidence of Rule 14a-19 compliance at least 5 business days before meeting.
January 12, 2023, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Forte Biosciences appoints David Gryska to board; Patricia Walker resigns

David Gryska appointed as Class II director effective January 10, 2023; serves on Audit Committee.
November 14, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 5.02 item 7.01 item 9.01 ◈ Earnings Releases◈ executive_change

Forte Biosciences Q3 net loss narrows to $0.18/sh; cash $44M; appoints Scott Brun to board

Q3 2022 net loss $3.4M ($0.18/share) vs $7.8M ($0.54) in Q3 2021; R&D expenses fell to $1.4M.
August 15, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 8.01 item 9.01

Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024

Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.
August 12, 2022, 7:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Forte Biosciences files prospectus supplement for additional $2.7M ATM offering

Filed new prospectus supplement for sale of up to $2.7M of common stock via existing ATM agreement with Ladenburg Thalmann.
July 12, 2022, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.03 item 5.03 item 9.01

Forte Biosciences adopts poison pill rights plan with 10% trigger

Board declares dividend of one Right per share of common stock; record date July 21, 2022.
June 7, 2022, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Forte Biosciences appoints Dr. Hubert Chen as President and CSO

Dr. Chen appointed President and Chief Scientific Officer effective June 7, 2022; Paul Wagner remains CEO.
June 2, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan

Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.
May 16, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 5.02 item 7.01 item 9.01 ◈ executive_change

Forte Biosciences Q1 net loss $2.6M; cash $40M to fund operations for 24 months

Net loss of $2.6M ($0.17 per share) vs $4.8M ($0.36) in Q1 2021; R&D spend down to $0.7M on wind-down of FB-401.
April 1, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Forte Biosciences enters ATM equity sales agreement for up to $25M

Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.
March 18, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors

Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.
February 2, 2022, 6:59 PM ET other material materiality 0.55 neutral item 1.02

Forte Biosciences terminates patent license agreement with NIAID, effective April 2, 2022

Terminated Patent License Agreement with National Institute of Allergy and Infectious Diseases (NIAID).
September 2, 2021, 7:59 PM ET other material materiality 0.95 negative item 8.01 item 9.01

Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50

Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.